General Information
Viking NASH VK2809-202
VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week off-drug Phase in Subjects with Non-Alcoholic Steatohepatitis
| Protocol | VK2809-202 |
|---|---|
| Identifier | |
| UID | 735a0b2f-9963-4a2f-a556-d75df3dc7290 |
| Status | Done - Archived |
| Phase | 2B |
| Category | NASH / Adult |
| Launch Year | 2020 |
| NCT Number | - |
| Created | 2019-08-30 16:42 |
| Last Updated | 2024-05-02 17:02 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2022-12-31 | No |
| Enrollment Open | 2020-02-24 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2020-01-23 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2024-04-24 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Viking |
|---|---|
| Division | Viking |
| Team | Viking |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Covance -LabCorp Drug Development |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
